A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT07570823 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

101

Enrollment

INDUSTRY

Sponsor class

Conditions

DLBCL - Diffuse Large B Cell Lymphoma

Interventions

DRUG: SCTB35 injection
DRUG: Rituxumab
DRUG: Gemcitabine
DRUG: Oxaliplatin

Sponsor

Sinocelltech Ltd.